Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade

44Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The time course of recovery of [3H]spiperone binding in the rat striatum after administration of the irreversible antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) was studied in chronically haloperidol-treated rats (0.5 mg/kg, i.p., twice a day for two weeks). Chronic neuroleptic treatment significantly enhanced the [3H]spiperone Bmax value. EEDQ (6.0 mg/kg, i.p.) produced a similar profound decrease of [3H]spiperone binding site density in both saline- and haloperidol-treated rats. However, the receptor degradation rate constant in the haloperidol-treated animals (k = 0.0051 h-1) and the receptor production rate (r = 1.6 fmol/mg prot/h) were lower than in the saline-treated rats (k = 0.0074 h-1; r = 1.8 fmol/mg prot/h). These results are different from what is found in 6-OH-dopamine lesioned rats. D2-receptor recovery after EEDQ administration is enhanced in chronically (4-5 weeks) denervated striatum (Brain Research, 329 (1985) 225-231) while the degradation rate constant is unchanged. Thus, the present results indicate that chronic haloperidol treatment reduces both the degradation and production rates of striatal D2-receptors. © 1987.

Cite

CITATION STYLE

APA

Pich, E. M., Benfenati, F., Farabegoli, C., Fuxe, K., Meller, E., Aronsson, M., … Agnati, L. F. (1987). Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade. Brain Research, 435(1–2), 147–152. https://doi.org/10.1016/0006-8993(87)91595-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free